Comparison of compound A concentrations with sevoflurane anaesthesia using a closed system with a PhysioFlex anaesthesia machine vs a low-flow system with a conventional anaesthesia machine

British Journal of Anaesthesia

Volumn 84, Issue 3, 2000, Pages 350-353

  Bito, H ^a   Suzuki, A ^a   Sanjo, Y ^a   Katoh, T ^a   Sato, S ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaesthetics volatile, sevoflurane; Equipment, anaesthesia machines

Indexed keywords

CALCIUM OXIDE; CARBON DIOXIDE; COMPOUND A; DRUG METABOLITE; INORGANIC COMPOUND; SEVOFLURANE; UNCLASSIFIED DRUG;

ADSORPTION; ADULT; AGED; ANESTHESIA; ANESTHETIC EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG DEGRADATION; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; TEMPERATURE;

EID: 0034004777     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bja.a013438     Document Type: Article

References (33)

1. Wallin RF, Regan BM, Napoli MD, Stern IJ. Sevoflurane: A new inhalational anesthetic agent. Anesth Analg 1975; 54: 758-65
2. Morio M, Fujii K, Satoh N, et al. Reaction of sevoflurane and its degradation products with soda lime: Toxicity of the byproducts. Anesthesiology 1992; 77: 1155-64
3. Gonsowski CT, Laster MJ, Eger El II, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats: Effect of a 3-hour administration. AnesthesioJogy 1994; 80: 556-65
4. Gonsowski CT, Laster MJ, Eger El II, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats: Effect of increasing duration of administration. Anesthesiology 1994; 80: 566-73
5. Kandel L, Laster MJ, Eger El II, Kerschmann RL, Martin J. Nephrotoxicity in rats undergoing a one-hour exposure to compound A. Anesth Analg 1995; 81: 559-63
6. Keller KA, Callan C, Prokocimer P, et al. Inhalation toxicity study of a haloalkene degradant of sevoflurane, compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 1995; 83: 1220-32
7. Verkaaik AP, Erdmann W. Respiratory diagnostic possibilities during closed circuit anesthesia. Acta Anaesth Belg 1990; 41: 177-88
8. Biro P. Anaesthetic gas consumption and costs in a closed system with the PhysioFlex anaesthesia equipment. Anaesthesist 1993; 42: 638-43
9. Verkaaik APK, Van Dijk G. High flow closed circuit anaesthesia. Anaesth Intensive Core 1994; 22: 426-34
10. Hargasser S, Breinbauer B, Kling M, et al. Anaesthesia with the closed PhysioFlex system in comparison with conventional anaesthesia procedures. Anaesthesiol Reanim 1994; 19: 149-54
11. Wissing H, Kuhn I, Kessler P. The temperature-humidity profile of PhysioFlex. Study on a model. Anaesthesist 1997; 46: 201-6
12. Bito H, Ikeda K. Closed-circuit anesthesia with sevoflurane in humans: Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit. Anesthesiology 1994; 80: 71-6
13. 2 absorbants during low-flow anesthesia in surgical patients. Anesthesiology 1992; 77: 1064-9
14. Bito H, Ikeda K. Long-duration, low-flow sevoflurane anesthesia using two carbon dioxide absorbents: Quantification of degradation products in the circuit. Anesthesiology 1994; 81: 340-5
15. Bito H, Ikeda K. Effect of total flow rate on the concentration of degradation products generated by reaction between sevoflurane and soda lime. Br J Anaesth 1995; 74: 667-9
16. Munday IT, Ward PM, Foden ND, Jones RM, Van Pelt FNAM, Kenna JG. Sevoflurane degradation by soda lime in a circle breathing system. Anaesthesia 1996; 51: 622-6
17. Cunningham DD, Huang S, Webster J, Mayoral J, Grabenkort RW. Sevoflurane degradation to compound A in anaesthesia breathing systems. Br J Anaesth 1996; 77: 537-43
18. Ruzicka JA, Hidalgo JC, Tinker JH, Baker MT. Inhibition of volatile sevoflurane degradation product formation in an anesthesia circuit by a reduction in soda lime temperature. Anesthesiology 1994; 81: 238-44
19. Fang ZX, Eger El II. Factors affecting the concentration of compound A resulting from the degradation of sevoflurane by soda lime and Baralyme in a standard anesthetic circuit. Anesth Analg 1995; 81: 564-8
20. Fang ZX, Kandel L, Laster MJ, Ionescu P, Eger El II. Factors affecting production of compound A from the interaction of sevoflurane with Baralyme and soda lime. Anesth Analg 1996; 82: 775-81
21. Bito H, Ikeda K. Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Anesth Analg 1996; 82: 173-6
22. Bito H, Ikeuchi Y, Ikeda K. Effects of low-flow sevoflurane anesthsia on renal function: Comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia. Anesthesiology 1997; 86: 1231-7
23. Kharasch ED, Frink EJ jr, Zager R, Bowdle TA, Artru A, Nogami WM. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Anesthesiology 1997; 86: 1238-53
24. Ebert TJ, Frink EJ, Kharasch ED. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. Anesthesiology 1998; 88: 601-10
25. Ebert TJ, Messana LD, Uhrich TD, Staacke TS. Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers. Anesth Analg 1998; 86: 662-7
26. Mazze RI, Friedman M, Delgado-Herrera L, Galvez ST, Mayer DB. Toxicity of compound A plus sevoflurane compared with isoflurane in non-human primates. Anesthesiology 1998; 89: A490
27. Iyer RA, Anders MW. Cysteine conjugate β-lyase-dependent biotransformation of the cysteine s-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria. Anesthesiology 1996; 85: 1454-61
28. Iyer RA, Frink EJ, Ebert TJ, Anders MW. Cysteine conjugate β-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A. Anesthesiology 1998; 88: 611-18
29. Uttamsingh V, Iyer RA, Baggs RB, Anders MW. Fate and toxicity of 2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene (compound A)-derived mercapturates in male, Fischer 344 rats. Anesthesiology 1998; 89: 1174-83
30. Kharasch ED, Thorning D, Garton K, Hankins DC, Kilty CG. Role of renal cysteine conjugate β-lyase in the mechanism of compound A nephrotoxicity in rats. Anesthesiology 1997; 86: 160-71
31. Kharasch ED, Hoffman GM, Thorning D, Hankins DC, Kilty CG. Role of renal cysteine conjugate β-lyase pathway in inhaled compound A nephrotoxicity in rats. Anesthesiology 1998; 88: 1624-33
32. Eger El II, Koblin DD, Bowland T, et al. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 1997; 84: 160-8
33. Eger El II, Gong D, Koblin DD, et al. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 1997; 85: 1154-63